Effects of a factor Xa inhibitor, DX-9065a, in a novel rabbit model of venous thrombosis

Basic Research in Cardiology

Volumn 94, Issue 1, 1999, Pages 15-22

  Rogers, K L ^a   Chi, L ^a   Rapundalo, S T ^a   Kramer, J B ^a   Gallagher, K P ^a  

^a PFIZER INC   (United States)

Author keywords

Antithrombotic; DX 9065a; Factor X inhibitor; Rabbit model; Venous thrombosis

Indexed keywords

2 [4 [(1 ACETIMIDOYL 3 PYRROLIDINYL)OXY]PHENYL] 3 (7 AMIDINO 2 NAPHTHYL)PROPIONIC ACID; BLOOD CLOTTING FACTOR 10A INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLEEDING TIME; BLOOD CLOTTING TIME; BLOOD FLOW; BOLUS INJECTION; CAVA VEIN; CONTINUOUS INFUSION; DOSE RESPONSE; INTRAVENOUS DRUG ADMINISTRATION; MALE; NONHUMAN; PARTIAL THROMBOPLASTIN TIME; PROTHROMBIN TIME; RABBIT; THROMBIN TIME; VEIN THROMBOSIS;

ADMINISTRATION, ORAL; ANIMALS; ANTICOAGULANTS; DISEASE MODELS, ANIMAL; FACTOR XA; HEMOSTASIS; INJECTIONS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS; MALE; NAPHTHALENES; PLATELET AGGREGATION INHIBITORS; PROPIONIC ACIDS; RABBITS; SERINE PROTEINASE INHIBITORS; VENOUS THROMBOSIS;

EID: 0032961442     PISSN: 03008428     EISSN: None     Source Type: Journal    
DOI: 10.1007/s003950050122     Document Type: Article

References (22)

1. Cappello M, Hawdon JM, Jones BF, Kennedy WP, Hotez PJ (1996) Ancylostoma caninum anticoagulant peptide: Cloning by PCR and expression of soluble, active protein in E. coli. Mol Biochem Parasitol 80 (1): 113-117
2. Carteaux JP, Gast A, Tschopp TB, Roux S (1995) Activated clotting time as an appropriate test to compare heparin and direct thrombin inhibitors such as hirudin or Ro 46-6240 in experimental arterial thrombosis. Circulation 91: 1568-1574
3. Chi L, Saganek LJ, Rogers KL, Mertz TE, Metz AL, Uprichard CG, Gallagher KP (1998) A novel model of venous thrombosis in the vena cava of rabbits. J Pharmacol Toxicol Methods
4. Chi L, Rogers KL, Uprichard ACG, Gallagher KP (1997) The therapeutic potential of novel anticoagulants. Exp Opin Invest Drugs 6: 1591-1622
5. Hara T, Yokoyama A, Ishihara H, Yokoyama Y, Nagahara T, Iwamoto M (1994) DX-9065a, a new synthetic, potent anticoagulant and selective inhibitor for factor Xa. Thromb Haemost 71 (3): 314-319
6. Hara T, Yokoyama A, Morishima Y, Kunitada S (1995) Species differences in anticoagulant and anti-Xa activity of DX-9065a, a highly selective factor Xa inhibitor. Thromb Res 80 (1): 99-104
7. Hara T, Yokoyama A, Tanabe K, Ishihara H, Iwamoto M (1995) DX-9065a, an orally active, specific inhibitor of factor Xa, inhibits thrombosis without affecting bleeding time in rats. Thromb Haemost 74 (2): 635-639
8. Herbert JM, Bernat A, Dol F, Herault JP, Crepon B, Lormeau JC (1996) DX-9065a, a novel, synthetic, selective and orally active inhibitor of factor Xa: in vitro and in vivo studies. J Pharmacol Exp Ther 276 (3): 1030-1038
9. Hollenbach SJ, Wong AG, Ku P, Needham KM, Lin PH, Sinha U (1995) Efficacy of "fXa inhibitors" in a rabbit model of venous thrombosis. Circulation Supp I 92 (8): I-486-487
10. Morishima Y, Tanabe K, Terada Y, Hara T, Kunitada S (1997) Antithrombotic and hemorrhagic effects of DX-9065a, a direct and selective factor Xa inhibitor: Comparison with a direct thrombin inhibitor and antithrombin III-dependent anticoagulants. Thromb Haemost 78: 1366-1371
11. Nagahara T, Yokoyama Y, Inamura K, Katakura S, Komoriya S, Yamaguchi H, Hara T, Iwamoto M (1994) Dibasic (amidinoaryl) propanoic acid derivatives as novel blood coagulation factor Xa inhibitors. J Med Chem 37: 1200-1207
12. Nicolini FA, Lee P, Malycky JL, Lefkovits J, Kottke-Marchant K, Plow EF, Topol EJ (1996) Selective inhibition of factor Xa during thrombolytic therapy markedly improves coronary artery patency in a canine model of coronary thrombosis. Blood Coagul Fibrin 7(1): 39-48
13. Nutt EM, Jain D, Lenny AB, Schaffer L, Siegl PK, Dunwiddie CT (1991) Purification and characterization of recombinant antistasin: A leech-derived inhibitor of coagulation factor Xa. Archives Biochem and Biophysics 285 (1): 37-44
14. Roux S, Tschopp T, Baumgartner HR (1996) Effects of napsagatran (Ro 46-6240), a new synthetic thrombin inhibitor and of heparin in a canine model of coronary artery thrombosis: Comparison with an ex vivo annular perfusion chamber model. J Pharmacol Exp Ther 277 (1): 71-78
15. Schaffer LW, Davidson JT, Vlasuk GP, Siegel PKS (1991) Antithrombotic efficiency of recombinant tick anticoagulant peptide. Circulation 84: 1741-1748
16. Thomas DP (1996) Venous thrombosis and the "Wessler test". Thromb Haemost 76: 1-4
17. Vlasuk GP, Dempsey EM, Oldeschulte GL, Bernardino VT, Richard BM, Rote WE (1995) Evaluation of a novel small protein inhibitor of blood coagulation factor Xa (rNAP-5) in animal models of thrombosis. Circulation Supp 192 (8): I-685
18. Waxman L, Smith DE, Arcuri KE, Vlasuk GP (1990) Tick anticoagulant peptide (TAP) is a novel inhibitor of blood coagulation factor Xa. Science 248: 593-596
19. Wong PC, Crain EJ, Nguan O, Watson CA, Racanelli A (1996) Antithrombotic actions of selective inhibitors of blood coagulation factor Xa in rat models of thrombosis. Thromb Res 83 (2): 117-126
20. Yamashita T, Tsuji T, Matsuoka A, Giddings JC, Yamamoto J (1997) The antithrombotic effect of synthetic low molecular weight human factor Xa inhibitor, DX-9065a, on He-Ne laser-induced thrombosis in rat mesenteric microvessels. Thromb Res 85 (1): 45-51
21. Yamazaki M, Asakura H, Aoshima K, Saito M, Jokaji H, Uotani C, Kumabashiri I, Morishita E, Ikeda T, Matsuda T (1994) Effects of DX-9065a, an orally active, newly synthesized and specific inhibitor of factor Xa, against experimental disseminated intravascular coagulation in rats. Thromb Haemost 72 (3): 393-396
22. YokoyamaT, Kelly AB, Marzec UM, Hanson SR, Kunitada S, Harker LA (1995) Antithrombotic effects of orally active synthetic antagonists of activated factor X in nonhuman primates. Circulation 92 (3): 485-491